Cipla Ltd. — Regulatory Filings 2020

Jun 18, 2020

==> picture [107 x 36] intentionally omitted <==

18[th] June 2020

(1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

• (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Press Release – Cipla expands partnership with Roche Pharma India to further improve

access to key oncology medicines

Dear Sir/Madam,

Please find enclosed press release dated 18[th] June 2020 for the captioned subject.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully, For Cipla Limited

RAJENDRA CHOPRA Digitally signed by RAJENDRA CHOPRA DN: c=IN, o=Personal, 2.5.4.20=4987ad48c3965cfde78c8ea69e6f40ac91535876f12ba1fa5ba45cc5cc8db6cb, postalCode=122001, st=HARYANA, serialNumber=0be85c0408d0e3afd663669f5314248a72fdcdf34d01d48d472d7cf9262696f6, cn=RAJENDRA CHOPRA Date: 2020.06.18 17:14:04 +05'30'

Rajendra Chopra Company Secretary

Encl: as above

Prepared by: Juzer Masta

==> picture [609 x 69] intentionally omitted <==

==> picture [107 x 36] intentionally omitted <==

Press Release

Cipla expands partnership with Roche Pharma India to further improve access to key oncology medicines

• Cipla signs a distribution agreement with Roche Products (India) Pvt. Ltd. to expand scope of the partnership to include, marketing and distribution of Roche’s trademark oncology drugs - Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova) in India

Mumbai 18[th] June 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") and Roche Products (India) Pvt. Ltd. (Roche Pharma) today announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India. Under this agreement, Cipla will be responsible for marketing and distribution of Roche Pharma’s key trademark oncology drugs viz.,Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova).

Roche and Cipla had previously entered into a similar agreement in February 2018 for promotion and distribution of Tocilizumab (Actemra) and other products.

Commenting on the partnership, Nikhil Chopra, Executive Vice President & CEO - India Business, Cipla said, “ Enabling access to high quality life-saving treatments is core to our purpose of ‘Caring for Life’. We are pleased to strengthen our partnership with Roche towards bringing innovative oncology medications to India. This represents our unwavering commitment to address the unmet needs of cancer patients through an enhanced portfolio of offerings in this space. We look forward to leveraging our solid marketing and distribution strengths in India to provide broader access to such transformative treatments in the country” .

==> picture [612 x 90] intentionally omitted <==

==> picture [107 x 36] intentionally omitted <==

“ We have been working as a partner with Cipla for some of our products and it has been a great journey working with them in ensuring access to our innovations in India. We hope to extend the same support to patients in India through this new agreement.”, said V. Simpson Emmanuel, General Manager, Roche Products (India) Pvt. Ltd . “This deal will ensure that our focus on providing Roche innovations in India remains steadfast in this portfolio and we will keep on collaborating with the relevant stakeholders in Indian healthcare system to ensure better outcomes for patients.”

About Roche Products (India) Pvt. Ltd.

Roche Products (India) Private Limited was incorporated in 1994 as a wholly owned subsidiary of the Roche Group, headquartered in Basel, Switzerland. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

For more than 60 years, Roche has been committed to making a difference to the lives of people in India. Today, Roche is the leader in oncology treatment in India; apart from cancer, Roche’s has innovative medicines in other therapy areas too: transplantation, rheumatoid arthritis (RA), and chronic kidney disease (CKD)-related anaemia. Roche believes in making the latest and most innovative medicines accessible to patients in India in the fastest possible time.

Roche has been developing medicines with the goal to redefine treatment in oncology over the last 50 years. Today, Roche is investing more than ever in our effort to bring innovative treatment options that help a person’s own immune system fight cancer. For more information on Roche Pharma India, visit www.rocheindia.com

==> picture [612 x 90] intentionally omitted <==

==> picture [107 x 36] intentionally omitted <==

About Cipla :

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT May’20), 3rd largest in the pharma private market in South Africa (IQVIA MAT Mar’20), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact:

Corporate Communications Investor Relations

Heena Kanal Naveen Bansal E-Mail: CorpComm@cipla.com E-Mail: Investor.Relations@cipla.com

==> picture [612 x 90] intentionally omitted <==